Ash 2021 – why Breyanzi and Yescarta might refresh the parts Kymriah cannot reach
Novartis will not pursue Kymriah’s use in second-line lymphoma; but have Breyanzi and Yescarta proved enough to be filed in this setting?
Ash 2021 – the sun sets on Kymriah, but Novartis has a plan
Novartis unveils the first clinical backing for a two-day manufacturing technique that it hopes will recharge its Car-T efforts.
Gilead pause adds to Merck’s HIV doubts
Could Gilead soon be looking for a new partner for its long-acting project lenacapavir?
Arcus’s near dream scenario
Gilead opts in at long last, and that’s more than many might have been expecting.
Astra presses on with bispecifics
Followers of novel immuno-oncology mechanisms will note Astrazeneca as a new player in Tigit and Tim3.
SITC 2021 – ALX Oncology's unpleasant double dip
Evorpacept adds a solid tumour setback to last week’s disappointment in blood cancers, and the CD47 bubble deflates.
